Recent developments include the company’s IPO completion in February 2025 and plans to showcase innovative diagnostic solutions at international exhibitions in May 2025.

• Anbio Biotechnology completed its initial public offering on February 20, 2025, raising $8 million on Nasdaq by issuing 1,600,000 Class A Ordinary Shares at $5.00 per share [N2].
• The company announced plans to showcase innovative diagnostic solutions at key international exhibitions scheduled for May 2025 [N1].

Anbio Biotechnology has demonstrated revenue growth and improved profitability with a high gross margin and strong liquidity. The company’s diversified IVD product portfolio and readiness for commercialization across multiple platforms provide a foundation for market penetration. Expansion into veterinary diagnostics and advanced therapeutic areas could broaden revenue streams and reduce dependence on pandemic-related products. Experienced management and governance structures support strategic execution. The company’s cost control measures and supplier agreements contribute to improved margins and operational efficiency.

The company faces risks related to market acceptance of its IVD products globally, including regulatory approvals and competition in a rapidly evolving diagnostic market. Expansion into new sectors such as veterinary diagnostics and advanced therapies involves regulatory, commercialization, and operational challenges that could delay or limit success. Supply chain disruptions or increases in reagent and consumable costs could adversely affect profitability. The company’s limited operating history prior to 2021 and reliance on pandemic-related products in earlier years may pose challenges in sustaining growth. Additionally, the incentive compensation plan is contingent on achieving a high market capitalization, which may not be attained.

Anbio Biotechnology’s moat is based on its diversified and scientifically validated IVD product portfolio spanning multiple diagnostic platforms and health areas. The company’s established commercial readiness of products, combined with completed clinical and analytical validation, supports market entry. Its strategic expansion into veterinary diagnostics and advanced therapies aims to broaden its addressable market. The company’s experienced management team with integrated expertise in biologics, diagnostics, and business development enhances its ability to execute. Strong supplier relationships and contractual agreements help manage procurement costs and supply chain risks. However, the diagnostic market is characterized by rapid technological change and regulatory complexity, which require ongoing innovation and compliance to maintain competitive positioning.

• Market Acceptance and Regulatory Risks: The commercial success of Anbio’s IVD products depends on acceptance by healthcare providers, regulatory authorities, and customers globally. Failure to obtain or maintain regulatory approvals or to meet compliance requirements could adversely affect sales.
• Supply Chain and Cost Risks: The company relies on suppliers for reagents and consumables. Increases in prices or supply disruptions could negatively impact profitability. Logistic issues related to medical device exports may cause delays and affect customer satisfaction.
• Expansion and Diversification Risks: Efforts to expand into veterinary diagnostics and advanced therapeutic areas involve regulatory approvals, validation studies, and commercialization efforts that may face delays or fail to achieve expected adoption.
• Financial and Operational Risks: The company’s financial performance depends on continued revenue growth and cost control. Failure to manage expenses or secure additional financing if needed could limit operations and growth.

• Anbio Biotechnology is a medical device company specializing in in vitro diagnostics (IVD) with a mission to personalize and decentralize diagnostic solutions globally for faster diagnosis and improved patient prognosis.
• The company offers laboratory, wellness, at-home, and point-of-care IVD products covering detection of infectious diseases, inflammation, cerebral apoplexy, glycuresis, kidney function, cancer, bone health, digestive tract health, thyroid health, pharmacogenomics, cardiovascular, allergy, diabetes, hormones, and drugs of abuse.
• Anbio Biotechnology was incorporated on July 27, 2021, under Cayman Islands law and operates primarily through its entity Anbio Biotechnology Limited (Samoa) after selling Anbio Biotechnology Limited (BVI) in 2025.
• The company completed its initial public offering on February 20, 2025, raising $8 million by issuing 1,600,000 Class A Ordinary Shares at $5.00 per share.
• Revenue for the year ended December 31, 2025 was approximately $8.65 million, up 5.64% from 2024, driven by increased orders and demand for customized products, with 80.4% of 2025 IVD revenue from non-COVID products.
• Net income for 2025 was $6.4 million, a 169.9% increase from 2024, reflecting improved profitability and cost control.
• Gross margin improved to approximately 87.2% in 2025 from 71.9% in 2024, due to higher-margin products and procurement cost control.
• Cost of revenue decreased significantly in 2025 due to product mix shift and selective customer screening focusing on higher-margin sales.
• Selling, general and administrative expenses decreased by 54.18% in 2025 compared to 2024, reflecting reduced professional fees and cost control.
• Research and development expenses decreased in 2025 as commercialized products matured, focusing R&D on regulatory compliance and market expansion rather than new product development.
• The company’s liquidity as of December 31, 2025 included cash and cash equivalents of approximately $7.77 million, short-term investments of $4.13 million, current assets of $30.24 million, and current liabilities of $87,836, resulting in a very strong current ratio of 344.31 and cash ratio of 135.49.
• Anbio Biotechnology’s IVD product portfolio includes six platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR), Loop-mediated Isothermal Amplification (LAMP), and Dry Chemistry.
• All supplied IVD products are ready for commercialization with completed clinical and analytical validation studies; regulatory registration is required before sales in the European Union.
• The company is expanding into new sectors including veterinary diagnostics and advanced therapeutic areas, aiming to diversify revenue and reduce reliance on pandemic-related products.
• Management includes CEO Michael Lau with extensive experience in life sciences and CDMO business development, CFO Suki Song with over 20 years in public accounting and financial management, and CBO Chris Tian with biotechnology industry experience.
• The company has a board of directors with a majority independent members and has adopted an Executive Compensation Recovery Policy (Clawback Policy) in line with Nasdaq standards.
• Anbio Biotechnology plans incentive compensation for executives contingent on achieving a market capitalization target of $1 billion for six consecutive months.
• The company has no significant off-balance sheet arrangements as of December 31, 2025.
• Recent developments include the IPO closing in February 2025 and plans to showcase innovative diagnostic solutions at international exhibitions in May 2025.